Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Net Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Net Margin for 16 consecutive years, with 4.93% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 5840.0% to 4.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.8% through Dec 2025, up 3886.0% year-over-year, with the annual reading at 0.8% for FY2025, 3886.0% up from the prior year.
  • Net Margin for Q4 2025 was 4.93% at Anika Therapeutics, down from 3.04% in the prior quarter.
  • The five-year high for Net Margin was 17.12% in Q2 2021, with the low at 506.35% in Q4 2023.
  • Average Net Margin over 5 years is 57.48%, with a median of 7.63% recorded in 2022.
  • The sharpest move saw Net Margin tumbled -41489bps in 2022, then soared 44302bps in 2024.
  • Over 5 years, Net Margin stood at 9.11% in 2021, then crashed by -4553bps to 424.0% in 2022, then decreased by -19bps to 506.35% in 2023, then soared by 87bps to 63.33% in 2024, then skyrocketed by 92bps to 4.93% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 4.93%, 3.04%, and 2.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.